Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. Our research is focused on developing novel immune modulating therapies in neuroscience/pain, virology, immuno-oncology and autoimmune diseases. Kineta’s AViiD™ Screening Platform is the discovery engine of our innate immune antiviral, vaccine adjuvant and immuno-oncology programs.
|Program||Therapeutic Focus||Discovery||Preclinical||Phase 1A||Phase 1B||Phase 2|
|AViiD™ Antiviral Discovery Platform||Broad-spectrum antivirals, vaccine|
adjuvants and immuno-oncology
|Proprietary Screening Platform|
|Innate Immune Antivirals||Broad spectrum antivirals|
Respiratory & emerging viruses
|LHF-535||Viral hemorrhagic fever|
|Dalazatide*||Lupus, Psoriasis, Vasculitis,|
RA, MS, IBD
*Jointly developed by Kineta Inc and its sister corporation KPI Therapeutics Inc.